Orforglipron vs Retatrutide
Overview
Orforglipron and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Orforglipron and Retatrutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Orforglipron | Retatrutide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | Clinical trials | Clinical trials |
| Frequency | daily | weekly |
| Reported benefits | Oral administration convenience, weight loss, glucose control | Enhanced weight loss beyond dual agonists, metabolic improvement |
| Reported side effects | Under investigation | Clinical trial phase |
Key differences
Primary use. Orforglipron is categorised under Weight Management & Metabolic, while Retatrutide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Orforglipron: FDA-approved. Retatrutide: not FDA-approved; treated as a research compound.
Dosing. Orforglipron is typically dosed at Clinical trials (daily). Retatrutide is typically dosed at Clinical trials (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Orforglipron and Retatrutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Orforglipron and Retatrutide?
- Orforglipron and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Orforglipron is FDA-approved for one or more indications, whereas Retatrutide is not FDA-approved; generally classified as a research compound.
- What is Orforglipron used for?
- Oral GLP-1.
- What is Retatrutide used for?
- Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.
- Can you take Orforglipron and Retatrutide together?
- Some users combine peptides within a single protocol, but stacking Orforglipron and Retatrutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Orforglipron or Retatrutide FDA-approved?
- Orforglipron is FDA-approved for one or more indications. Retatrutide is not FDA-approved; generally classified as a research compound.
Read the full articles
- Orforglipron — full monograph: mechanism, research, dosing & references
- Retatrutide — full monograph: mechanism, research, dosing & references